Would you incorporate a PARP inhibitor into the management of a patient with endometrial cancer with a germline or somatic BRCA mutation?
Would you consider utilizing both immunotherapy and a PARP inhibitor in a patient with both MMR deficiency and BRCA mutation?
Community PollStarted
When might you use a PARP inhibitor in the care of a patient with endometrial cancer found to have a BRCA mutation?
1 physician has voted
Join Mednetto vote and see how they answered.